-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

4038 Assessing Donor and Platelet Transfusion Characteristics on Intracranial Hemorrhage Outcomes

Program: Oral and Poster Abstracts
Session: 401. Blood Transfusion: Poster III
Hematology Disease Topics & Pathways:
Research, Bleeding and Clotting, bleeding disorders, Biological therapies, adult, Clinical Research, Diseases, real-world evidence, Therapies, Adverse Events, Transfusion, Study Population, Human
Monday, December 11, 2023, 6:00 PM-8:00 PM

David Roh, MD1*, Jonathan M Davis, PhD2*, Travis Lee, BS2*, Patrick M Mitchell, ScD2*, Deborah Bookwalter, ScD2*, Elizabeth Stone, MD/PhD3*, Matthew S. Karafin, MD/MS4*, Melissa M. Cushing, MD5*, Bryan R Spencer, PhD6*, Roberta Bruhn, MS/PhD7*, Jerome L. Gottschall, MD8*, Alan E. Mast, MD, PhD9, Ritchard G. Cable, MD10*, Steven Kleinman, MD11* and Eldad A. Hod, MD1

1Columbia University Irving Medical Center, New York, NY
2Westat, Rockville, MD
3Columbia University Irving Medical Center, New York, NY, USA, New York, NY
4Blood Research Center, University of North Carolina, Chapel Hill, NC
5Cornell University Medical Center, New York, NY
6American Red Cross, Boston, MA
7Vitalant Research Institute, San Francisco, CA
8Bloodcenter of Wisconsin, Milwaukee, WI
9Blood Center of Wisconsin, Milwaukee, WI
10American Red Cross Blood Svcs., Farmington, CT
11Kleinman Biomedical Research, Victoria, BC, CAN

Introduction: Intracranial hemorrhage (ICH) patients require rapid treatment to reverse coagulopathy, which can help establish hemorrhage control and improve outcomes. While acute platelet transfusions are given in ICH to reverse platelet dysfunction, delays in administration of hemorrhage control therapies and platelet unit characteristics themselves may impact the efficacy and clinical outcomes in different patient populations. Thus, we sought to evaluate the relationship of platelet transfusion timing and platelet unit characteristics with ICH mortality.

Methods: Available data for incident hospitalizations of adult ICH patients between 2019-2022 from 3 of the 5 participating sites within the multicenter REDS-IV-P network were assessed. ICH patients were included if they received ≥ 1 acute platelet transfusion within 48 hours of admission and presented with one of the following ICH etiologies: trauma (tICH), spontaneous intracerebral hemorrhage (sICH), and aneurysmal subarachnoid hemorrhage (aSAH). Patients with early withdrawal of care and death within the first 48 hours were excluded. Separate logistic regression models (each adjusting for age, sex, race/ethnicity, comorbidities, and number of platelet transfusions) assessed the relationship of 30 day ICH mortality outcome with the following: a) time to initial platelet transfusion in hour quartiles: <2.7 hours [reference] vs 2.7-5.6 hours vs 5.7-14.5 hours vs 14.6-48 hours, b) any major ABO incompatible platelet transfusion versus identical or minor mismatch, and c) any donor-recipient sex mismatched platelet transfusion. Separate subgroup analyses were performed by ICH etiologic subgroups.

Results: Amongst 619 ICH patients receiving an acute platelet transfusion, 52% were from tICH, 36% from sICH, and 12% from aSAH. Mortality was seen in 17% of the overall cohort. Longer times to platelet transfusion (longest quartile: 14.6-48 hours) were associated with mortality in the overall ICH cohort (adjusted OR 2.12; 95%CI: 1.10-4.12). In sICH, effect size estimates were notably greater with the longest quartile time to platelet transfusion also being associated with mortality (adjusted OR 4.66; 95%CI: 1.58-14.8). Longer times to platelet transfusion were not associated with mortality in tICH (adjusted OR 1.19; 95%CI: 0.45-3.15). Amongst 543 ICH patients with available donor-recipient ABO data, 32% received a major ABO incompatible platelet transfusion. While there was not an association of major ABO incompatible platelet transfusion with mortality in the overall cohort (adjusted OR 1.41; 95%CI 0.82-2.40), there again was a significant association of this exposure with mortality in the sICH subgroup (adjusted OR 3.06; 95%CI: 1.22-7.90). No associations of major ABO incompatible platelet transfusions were identified in tICH subgroup (adjusted OR 1.02; 95%CI: 0.49-2.10). We did not identify a relationship of sex mismatched platelet units with mortality in the overall ICH cohort or in any ICH subgroups.

Conclusions: In our analyses of data available from the REDS-IV-P network, we identified a suggestive relationship between longer times to platelet transfusion and mortality, but not of ABO mismatch in our overall ICH cohort. However, sICH may be a specific ICH subgroup more vulnerable to platelet transfusion characteristics and practices, particularly time to platelet transfusion and major ABO incompatible platelet unit exposures. Further work is necessary to assess the generalizability of our data and to clarify whether certain adult ICH patients require specially tailored platelet transfusion approaches.

Disclosures: Cushing: Cerus Corporation: Research Funding; Octapharma: Consultancy; Haemonetics: Membership on an entity's Board of Directors or advisory committees; Cerus Corporation: Membership on an entity's Board of Directors or advisory committees; CSL Behring: Membership on an entity's Board of Directors or advisory committees. Mast: Novo Nordisk: Consultancy, Research Funding.

*signifies non-member of ASH